BioWa and Sanofi-Aventis have signed a deal in which Sanofi gains non-exclusive rights to BioWa's Potelligent technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC). Potelligent Technology improves potency and efficacy of antibody therapeutics by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics.
Sanofi will develop an unspecified number of targets using BioWa's technology. BioWa will receive upfront payments, and may receive development milestone payments and royalties on products. Other details of the agreement are not disclosed.
"By working with BioWa's Potelligent Technology, we will further improve the mechanism of action of our therapeutic antibodies and make them more potent and more effective against targeted diseases," added Jean-Marc Herbert, Senior Vice President Discovery Research, Sanofi-Aventis.
Add this page to your favorite Social Bookmarking websites
BioWa and Sanofi-Aventis have signed a deal in which Sanofi gains non-exclusive rights to BioWa's Potelligent technology platform for the research, development and commercialization of their antibody therapies with enhanced antibody-dependent cellular cytotoxicity (ADCC). Potelligent Technology improves potency and efficacy of antibody therapeutics by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics.
